Chinese researchers at Nantong University say that testing the expression of a protein called TSPAN1 in tissues can prove useful in evaluating the prognosis of colorectal cancer patients.
Chinese researchers at Nantong University say that testing the expression of a protein called TSPAN1 in tissues can prove useful in evaluating the prognosis of colorectal cancer patients.
In a recent study, published in the World Journal of Gastroenterology, the researchers investigated the association between this protein and human colorectal adenocarcinoma.
Colorectal Cancer - Types, Causes, Risk Factors, Symptoms, Diagnosis, Treatment, Prognosis & Prevention
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancer is the third most common cancer in men.
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancer is the third most common cancer in men.
The researcher further revealed that 88 specimens of human colorectal adenocarcinoma were surgically removed.
TSPAN1 protein levels in cancer tissues were determined by immunohistochemistry using a polyclonal antibody against self-prepared TSPAN1.
Tumor Markers - For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.
Dr. Zhu and colleagues say that patients with TSPAN1 protein over expression were found to have a significantly shorter survival period than that in patients with TSPAN1 protein negative or weak expression, respectively.
Advertisement
Based on their observations, the researchers came to the conclusion that testing TSPAN1 expression in tissues would be a useful tool to evaluate the prognosis of patients with colorectal cancer.
Advertisement
Is There Any Association Between COX2 and Colon Cancer?
Non-steroidal anti-inflammatory drugs (NSAIDs), which are known to reduce the risk of colon cancer, act directly on cyclooxygenase-2 (COX2) and reduce its activity.
Non-steroidal anti-inflammatory drugs (NSAIDs), which are known to reduce the risk of colon cancer, act directly on cyclooxygenase-2 (COX2) and reduce its activity.
LIN
